Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

NCT04780438 is registered in ClinicalTrials.gov with G.Gennimatas General Hospital as lead sponsor.

NCT NCT04780438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04780438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.
Lead sponsor
G.Gennimatas General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
September 1, 2021
Completion date
December 1, 2023
Enrollment
350 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation recurrent, catheter ablation, pulmonary venous isolation, sodium-glucose co-transporter 2 inhibitors